Federal board approves $12.7 billion budget for Puerto Rico as island shakes off bankruptcy

SANJUAN,PuertoRico--AfederalcontrolboardthatoverseesPuertoRico’sfinancesonFridayapproveda$12.7billio 3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou




focus

author：leisure time    Page View：146
Adobe

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

advertisement

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Appeals court upholds Josh Duggar's conviction for downloading child sex abuse images
Next article： Dobbs anniversary: the lost opportunity of abortion as health care